Dyadic to Participate in Two Upcoming Investor Conferences
02 févr. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments
10 nov. 2022 16h00 HE
|
Dyadic International, Inc.
Received regulatory approval from South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for...
Dyadic to Present at Upcoming Industry and Investor Events in November
07 nov. 2022 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
27 oct. 2022 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Updates Market on Recent Scientific Achievements
13 sept. 2022 08h00 HE
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100
18 mars 2021 08h30 HE
|
Dyadic International, Inc.
Israel Institute for Biological Research (IIBR) reports successful challenge studies using human ACE2 transgenic mice vaccinated with SARS-CoV-2-S-RBD vaccine candidate manufactured from...
Akers Biosciences Announces a Leadership Change, Strategic Update, Legal Settlement and an AIM Update
08 oct. 2018 02h00 HE
|
Akers Biosciences Inc
THOROFARE, N.J., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies,...
Microbix Exhibiting at AACC Exposition
26 juil. 2018 07h00 HE
|
Microbix Biosystems Inc.
TORONTO, July 26, 2018 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX:MBX) (Microbix®), an innovator of biological products and technologies, announces that it will be exhibiting its Quality...
Microbix to Present at Okanagan Capital Conference
12 juil. 2018 07h00 HE
|
Microbix Biosystems Inc.
TORONTO, July 12, 2018 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX:MBX) (Microbix®), an innovator of biological products and technologies, announces that it will be presenting to investors...
VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
17 janv. 2018 08h00 HE
|
VBI Vaccines, Inc.
Two-part Phase 1/2a study of VBI-1901 to enroll patients with recurrent GBM Part A: Dose escalation to enroll up to 18 patientsPart B: Subsequent extension of optimal dose to enroll up to 10...